Cannabis-Induced Psychosis

What the research shows — in plain language

Cannabis is more available than it used to be. Many products are also much stronger. Most people who use cannabis never develop a serious mental illness. That is important to say first. At the same time, research over the last two decades has been consistent: cannabis can trigger a short-lived psychotic episode, and in some people it raises the chance of a longer-lasting psychotic illness such as schizophrenia.

This article explains what that means in everyday language. It is based on two landmark studies — one in the American Journal of Psychiatry (2018) and one in The Lancet Psychiatry (2019) — plus more recent research from 2024 through 2026.

What is psychosis?

Psychosis is a break from shared reality. A person may:

•      Hear voices or see things that are not there

•      Hold strong beliefs that are not true (for example, that people are watching or controlling them)

•      Feel intense paranoia

•      Have jumbled thinking that is hard to follow

These symptoms can last hours, days, or longer. They are frightening for the person and for family. They are also treatable. Early help matters.

Can cannabis actually cause this?

Yes — in some people, and especially with frequent use of high-THC products.

THC (tetrahydrocannabinol) is the chemical that makes someone feel “high.” It acts on brain systems that also play a role in psychosis. CBD (cannabidiol) is a different plant chemical. It does not produce a high and may even blunt some of THC’s effects. Many modern products are high in THC and low in CBD.

Researchers describe three related pictures:

1. During use: paranoia, odd thoughts, or brief hallucinations while high. These often fade as the drug wears off.

2. Cannabis-induced psychosis: symptoms that last beyond the high — hours to weeks — and may need emergency or hospital care.

3. Higher later risk of schizophrenia or bipolar disorder: especially after a cannabis-induced psychotic episode, heavy daily use, or use that starts in the teen years.

Cannabis is not the only cause of psychosis, and most users never become psychotic. Scientists describe it as one piece of a larger puzzle that also includes genes, early-life stress, and other factors. It is a piece we can change.

The 2018 American Journal of Psychiatry study

Starzer, Nordentoft, and Hjorthøj followed every person in Denmark diagnosed with a substance-induced psychosis between 1994 and 2014 — 6,788 people — for up to 20 years.

Key findings, in simple terms:

•      About 1 in 3 people with any drug-induced psychosis later developed schizophrenia or bipolar disorder.

•      Cannabis had the highest conversion rate of all substances. Almost half (47.4%) of people with cannabis-induced psychosis later received a diagnosis of schizophrenia or bipolar disorder.

•      About 41% converted specifically to schizophrenia.

•      Younger age at the first episode raised the chance of later schizophrenia.

•      Self-harm after the episode also raised later risk.

•      Half of the conversions to schizophrenia happened within about 3 years. Follow-up needs to last years, not weeks.

The takeaway for families and clinicians: a “drug psychosis” is not always a one-time event. For cannabis, it is often a warning sign that deserves close, long-term follow-up.

Source: Starzer MSK, Nordentoft M, Hjorthøj C. Am J Psychiatry. 2018;175(4):343-350.

The 2019 Lancet Psychiatry study (EU-GEI)

A large European research team compared 901 people with a first episode of psychosis to 1,237 people from the same cities who did not have psychosis. They asked about how often people used cannabis and how strong it was. “High-potency” meant products with about 10% THC or more — a level that is now common.

Key findings:

•      Daily cannabis use was linked to about 3 times higher odds of a psychotic disorder (adjusted odds ratio 3.2).

•      Daily use of high-potency cannabis was linked to nearly 5 times higher odds (adjusted odds ratio 4.8).

•      If high-potency cannabis had not been available, the authors estimated that about 12% of first-episode psychosis cases across the study sites might have been prevented. That figure rose to about 30% in London and about 50% in Amsterdam — cities where strong cannabis was widely used.

•      Starting high-potency cannabis at age 15 or younger also raised risk.

Cities with more daily use and more high-THC products had higher rates of new psychosis. That pattern is one reason public-health researchers take potency seriously.

Source: Di Forti M, Quattrone D, Freeman TP, et al. Lancet Psychiatry. 2019;6(5):427-436.

What newer research adds (2024–2026)

The picture has not softened. If anything, stronger products and wider access have made the signal clearer.

Cannabis is much stronger than it used to be. Average THC in dried cannabis has risen from around 4% in the early 2000s to more than 20% in many legal markets. Concentrates can be far higher. A 2025 summary in CMAJ noted this five-fold rise in potency.

Full psychotic episodes are uncommon — but not rare in the people we worry about most. A 2024 analysis of 162 studies found that about 1 in 200 cannabis-exposed people had a full psychotic episode. Milder psychotic-like symptoms were much more common in observational and lab studies (around 1 in 5). Risk was higher with a THC dose, younger age, and existing mental-health problems such as bipolar disorder.

High-THC products track with worse mental-health outcomes. A 2025 review of 99 studies in Annals of Internal Medicine found that high-concentration THC products were repeatedly linked to psychosis, schizophrenia, and cannabis use disorder. Studies that tried to use these products as treatment did not find a benefit for psychosis.

After legalization, a larger share of new schizophrenia cases has been tied to cannabis use disorder. In Ontario, Canada, the share of new schizophrenia diagnoses associated with cannabis use disorder rose from about 3.7% before legalization to about 10.3% after. The increase was largest in young men.

An emergency visit for cannabis-induced psychosis is a major red flag. In a study of 9.8 million people in Ontario, people seen in the ER for cannabis-induced psychosis had a dramatically higher 3-year risk of a schizophrenia-spectrum diagnosis than the general population.

Psychosis starts earlier in cannabis users. A 2026 meta-analysis of 149 studies (more than 70,000 people) found that cannabis users developed psychosis about 2.5 years earlier on average. The gap was larger when illness started later in adulthood.

Not every cannabis-induced psychosis becomes schizophrenia — but enough do that we should not wait and see. A 2026 review estimated that about 1 in 5 people with cannabis-induced psychosis later received a schizophrenia-spectrum diagnosis, and about 1 in 20 received a bipolar diagnosis. Danish long-term data remain higher (closer to 1 in 2 for any severe mood or psychotic illness). Different studies use different follow-up times, which explains the range. The clinical message is the same: stay close to care.

Adolescents are a special-risk group. The brain’s endocannabinoid system is still developing into the mid-20s. A large 2026 cohort of more than 460,000 adolescents found that cannabis use was linked to about double the later risk of a psychotic disorder and of bipolar disorder.

Who is at higher risk?

Risk is not the same for everyone. It is higher when several of these are true:

•      Use started in the teen years

•      Use is daily or near-daily

•      The product is high-THC (flower over about 10%, vapes, dabs, wax, many modern “medical” oils)

•      The product is a synthetic cannabinoid (Spice, K2, and similar “fake weed”). These are stronger at the brain’s cannabis receptor and more often cause severe, longer psychosis.

•      There is a family history of schizophrenia, bipolar disorder, or psychosis

•      The person already has anxiety, depression, bipolar disorder, or unusual perceptual experiences

•      There has already been one cannabis-related psychotic episode

Young men appear in several studies as a group with a rising share of cannabis-linked schizophrenia. That does not mean young women are safe. It means prevention conversations should start early for everyone.

What this does — and does not — mean

It does not mean every person who uses cannabis will become psychotic. Most will not.

It does mean:

•      “It is only plant medicine” is not a complete safety statement. Dose, potency, age, and personal vulnerability matter.

•      A first psychotic episode after cannabis use should be treated seriously, even if symptoms later settle.

•      Continuing to use cannabis after a psychotic illness is linked to more symptoms, more hospital stays, and more relapses.

•      Stopping or delaying use, especially in teens and young adults with a family history of psychosis, is one of the few risk factors we can actually change.

When to get help

Seek urgent care or call 911 if someone is a danger to self or others, or cannot tell what is real.

Call a clinician soon if you or a loved one has:

•      New paranoia, voices, or beliefs that do not match reality after using cannabis

•      Symptoms that last after the high is gone

•      A sudden drop in sleep, school, work, or self-care

•      A family history of psychosis plus increasing cannabis use

At LumiMind Psychiatry & Wellness we evaluate these symptoms carefully. Treatment may include a period of abstinence from cannabis, medication when needed, sleep support, and a plan to reduce future risk. Recovery is common when care starts early.

A note on medical cannabis in Florida

Florida has a medical cannabis program. A legal card does not remove psychiatric risk. Medical products can still be high in THC. If you have a personal or family history of psychosis, bipolar disorder, or a prior cannabis-related psychotic episode, talk with your psychiatric prescriber before using THC products. This is not a moral lecture. It is a safety conversation based on the studies above.

Bottom line

Two major papers — American Journal of Psychiatry in 2018 and The Lancet Psychiatry in 2019 — plus newer population studies through 2026, all point in the same direction. Frequent use of high-THC cannabis can trigger psychosis and raise the chance of a lasting psychotic illness, especially in young people and in those who have already had one episode. The risk is real, it is dose-related, and it is partly preventable.

If this topic touches you or someone you love, you do not have to sort it out alone.

Sources

1. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry. 2018;175(4):343-350.

2. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry. 2019;6(5):427-436.

3. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin. 2016;42(5):1262-1269.

4. Schoeler T, et al. Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research. Nature Mental Health. 2024.

5. Samet S, et al. High-concentration delta-9-THC cannabis products and mental health outcomes: systematic review. Annals of Internal Medicine. 2025.

6. Myran DT, et al. Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization. JAMA Network Open. 2025.

7. Li S, Solmi M, Myran DT, Fabiano N. Cannabis and psychosis. CMAJ. 2025;197(27):E810.

8. Stevens C, Large M, et al. Cannabis use and age at onset of psychosis: systematic review and meta-analysis. Biological Psychiatry. 2026.

9. Young-Wolff KC, et al. Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders. JAMA Health Forum. 2026.

10. Hasan A, et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World Journal of Biological Psychiatry. 2022;23(10).

This article is for education. It is not a diagnosis, a treatment plan, or a substitute for care from a licensed clinician who knows your history. If you are in crisis, call 988 or 911.

How to reach us

LumiMind Psychiatry & Wellness

Phone: 305-570-2885  •  Fax: 305-570-2887

Email: lumimindpsychwell@gmail.com

www.lumimindpsychiatrywellness.com